Good signs ...., page-452

evening

did we miss this one

regards



the diagnosis and treatment of cancer remains a critical priority for healthcare professionals around the world.

By putting digital pathology directly into the hands of surgeons as the operate, we can help facilitate on-the-spot decision making, treatment adjustments and precision surgery.

“We are particularly excited by what the InVue™, which tailors our patented technology to the surgical market, will mean for the future treatment and diagnosis of cancer patients. It will facilitate a dramatic step forward in the way cancer can be diagnosed and treated with unprecedented accuracy and precision. Our first intended use of InVue™ is for breast cancer surgery and margin determination. This form of cancer is the most commonly diagnosed cancer amongst women in Australia, with over 20,000 Australians diagnosed with breast cancer each year. In the US, this number is as high as 300,000.” said Dr Camile Farah, CEO and Managing Director of Optiscan Imaging Ltd.